Hyperprolactinemia in Patients with Psychiatric Illness: A Therapeutic Dilemma | Abstract

International Journal of Medical Research & Health Sciences (IJMRHS)
ISSN: 2319-5886 Indexed in: ESCI (Thomson Reuters)


Hyperprolactinemia in Patients with Psychiatric Illness: A Therapeutic Dilemma

Author(s):Riad A. Sulimani*

Hyperprolactinemia is a frequently observed condition among psychiatric patients. The causes of hyperprolactinemia can be varied. The most common one being antipsychotic medications and others may include conditions related to prolactin-secreting adenomas (prolactinomas). Dopamine Agonists (DAs) are medications that are commonly used for treating hyperprolactinemic states and prolactinomas. However, lately, there has been concern that DAs might carry a potential for aggravating the psychiatric illness, while antipsychotic medications have been condemned for aggravating hyperprolactinemic states. This review discusses the relationship between the two, and alternative treatment strategies to avoid these potentially serious interactions.

Select your language of interest to view the total content in your interested language

Scope Categories
  • Clinical Research
  • Epidemiology
  • Oncology
  • Biomedicine
  • Dentistry
  • Medical Education
  • Physiotherapy
  • Pulmonology
  • Nephrology
  • Gynaecology
  • Dermatology
  • Dermatoepidemiology
  • Otorhinolaryngology
  • Ophthalmology
  • Sexology
  • Osteology
  • Kinesiology
  • Neuroscience
  • Haematology
  • Psychology
  • Paediatrics
  • Angiology/Vascular Medicine
  • Critical care Medicine
  • Cardiology
  • Endocrinology
  • Gastroenterology
  • Infectious Diseases and Vaccinology
  • Hepatology
  • Geriatric Medicine
  • Bariatrics
  • Pharmacy and Nursing
  • Pharmacognosy and Phytochemistry
  • Radiobiology
  • Pharmacology
  • Toxicology
  • Clinical immunology
  • Clinical and Hospital Pharmacy
  • Cell Biology
  • Genomics and Proteomics
  • Pharmacogenomics
  • Bioinformatics and Biotechnology